CRISPR/Cas9-mediated interference and activation assays have demonstrated that rs11672691 variant is involved in the regulation of its eQTL genes PCAT19 and CEACAM21 expression and affects the cells’ aggressive property in prostate cancers (Gao et al., 2018). Here, CEACAM21 is linked to prostate cancer.